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Stat3 modulates chloride channel accessory protein
expression in normal and neoplastic mammary tissue
Katherine Hughes*,1, Maximilian Blanck2, Sara Pensa2,3 and Christine J Watson2
Mammary gland regression at the cessation of lactation (involution) is an exquisitely orchestrated process of cell death and tissue
remodelling in which Stat3 signalling has an essential role. The involution microenvironment of the mammary gland is considered
to be pro-tumourigenic and a proportion of cases of pregnancy-associated breast cancer are suggested to originate in tandem
with involution. However, the apparent paradox that STAT3 is required for cell death in normal mammary gland, but is associated
with breast cancer cell survival, has not been resolved. Herein, we investigate Stat3-mediated regulation of expression of members
of the calcium-activated chloride channel regulator (CLCA) family of proteins during involution and mammary carcinogenesis.
Using the conditionally immortal mammary epithelial cell line KIM-2, together with mice exhibiting mammary epithelial cell-specific
deletion of Stat3 during lactation, we demonstrate that expression of mCLCA1 and mCLCA2 is elevated in concert with activation
of Stat3. By contrast, murine CLCA5 (mCLCA5), the murine orthologue of human CLCA2, is significantly upregulated at 24, 72 and
96 h of involution in Stat3 knockout mice, suggesting a reciprocal regulation of these proteins by Stat3 in vivo. Interestingly,
orthotopic tumours arising from transplantation of 4T1 murine mammary tumour cells exhibit both phosphorylated Stat3 and
mCLCA5 expression. However, we demonstrate that expression is highly compartmentalized to distinct subpopulations of cells,
and that Stat3 retains a suppressive effect on mCLCA5 expression in 4T1 tumour cells. These findings enhance our understanding
of the regulation of CLCA channel expression both in vitro and in vivo, and in particular, demonstrate that expression of mCLCA1
and mCLCA2 during involution is profoundly dependent upon Stat3, whereas the relationship between mCLCA5 and Stat3 activity
is reciprocal and restricted to different subpopulations of cells.
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At the cessation of lactation, the two-phase process of
mammary gland involution restores the organ to near its pre-
pregnant state, and is exquisitely regulated by factors
including transforming growth factor-β3 during the first phase
of involution,1 IL-6 cytokine family members leukaemia
inhibitory factor (LIF) (first phase)2,3 and oncostatin M (OSM)
(second phase).4 These cytokines activate Stat3, a critical
transcriptional coordinator of the involution process.5,6 Thus,
mice with a mammary-specific conditional deletion of Stat3
exhibit markedly impaired involution and diminished cell
death.7–10
Although the initial phase of involution is reversible, the
second irreversible stage incorporates further cell death,
extensive tissue remodelling and acquisition of a ‘wound-
healing phenotype’.11 The inflammatory milieu of the involu-
tion mammary gland is considered to be pro-tumourigenic,
illustrated by mouse models of involution-associated
tumourigenesis.12,13 A corollary of these observations may
be found in epidemiological evidence from human breast
cancer indicating not only that a subgroup of cases of thewider
set of ‘pregnancy-associated breast cancers’ arises in the
post-partum period, but that this subset of patients may have a
poorer prognosis.14
Chloride channel accessory proteins, also known as
calcium-activated chloride channel regulators (CLCA pro-
teins), are a family of transmembrane proteins that have been
suggested to have a role in chloride conductance in epithelial
cells. Although the mechanism by which they activate other
channel proteins to trigger movement of chloride ions across
membranes is not clear, there is some evidence that they can
be secreted, and thereby potentially activate chloride
channels.15
CLCA proteins have been associated with diverse functions
including cell adhesion,16 apoptosis, tumourigenesis and
mucus cell differentiation.17 Of particular interest, both CLCA2
and CLCA4 have been shown to inhibit proliferation of breast
cancer cells when ectopically expressed in vitro,18 whereas
normal breast tissue exhibits high levels of CLCA2 in both
acini and small ducts.19 Murine CLCA5 (mCLCA5) is highly
homologous to human CLCA2 (hCLCA2) and is considered to
be its orthologue.20 Widely expressed in the cytoplasmic
granules of granular layer keratinocytes in stratified squamous
epithelia,21 mCLCA5 is downregulated in some murine
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mammary tumour cell lines, including 4T1 cells, where re-
expression inhibits proliferation.22 Thus, hCLCA2 and its
murine orthologue have been proposed as tumour suppressor
genes in breast cancer.23,24 However, other investigators have
demonstrated an upregulation of hCLCA2 in triple-negative
breast cancer patients with a poor prognosis,25 perhaps
suggesting breast cancer subtype specific roles, and exem-
plifying the need for further characterization of this poorly
understood protein family.
Other murine genes includemClca1 andmClca2 that share
~ 96% complementary DNA sequence identity, and encode
mCLCA1 and mCLCA2, respectively.26 These proteins are
reciprocally expressed during mammary gland development
with mCLCA2 being expressed at high levels during lactation
and involution, whereas mCLCA1 expression is suppressed
during involution.27 This pattern suggests different functional
roles for these highly related genes.
Given the pro-tumourigenic potential of the involution
mammary microenvironment, the critical role of Stat3 in
orchestrating regression and the intriguing regulation of
mCLCA proteins, we hypothesized that mammary epithelial
expression of Stat3 would influence the expression of mCLCA
proteins.
Results
Expression of mCLCA2 and mCLCA5 in mammary
epithelial KIM-2 cells is modulated by Stat3 activity. To
interrogate the hypothesis that mammary epithelial expres-
sion of Stat3 will influence the expression of mCLCA proteins,
we first wished to establish baseline levels of expression of
mCLCA2 and mCLCA5 in the KIM-2 conditionally immortal
mouse mammary epithelial cell line. KIM-2 cells were
maintained in an undifferentiated state and were subse-
quently differentiated by addition of lactogenic hormones,
resulting in the emergence of two phenotypically distinct
populations – an epithelial component expressing E-cad-
herin, and forming distinct islands and dome-like structures,
and a more loosely arranged population of elongated cells
around these islands (Figure 1a), as previously described.28
Differentiation was confirmed by robust upregulation in
expression of the milk protein β-casein (Figure 1b).
Figure 1 KIM-2 mammary epithelial cells exhibit upregulation of mCLCA2 and mCLCA5 expression upon differentiation, which persists during hormone withdrawal. (a) Upon
stimulation with prolactin, KIM-2 cells form dome-like epithelial islands (d), which exhibit robust E-cadherin expression, surrounded by more elongate, loosely arranged cells (l).
Immunofluorescence staining for E-cadherin (green) and DNA (Hoechst; blue). Right panel shows merged images. Scale bar= 100 μm. (b) RT-PCR analysis for mCLCA2,
mCLCA5, β-casein and cyclophilin A (housekeeping gene), in KIM-2 cells that are undifferentiated (undiff), KIM-2 cells that have received lactogenic hormones for 14 days (14d
Diff), or KIM-2 cells that have received lactogenic hormones for 11–14 days and have then undergone hormone withdrawal for 72 (72 h HW) or 96 h (96 h HW). Two independent
biological repeats of each condition are shown. (c) Expression of mCLCA2 and mCLCA5 in undifferentiated and differentiated KIM-2 cells, measured by qRT-PCR relative to
expression of cyclophilin A (housekeeping gene); values are mean±S.D. from at least three biological repeats; *Po0.05, as determined by Student’s t-test. NTC, no template
control
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Interestingly, both mCLCA2 and mCLCA5 exhibited a
pronounced upregulation in expression upon differentiation,
with mCLCA5 exhibiting higher levels of expression than
mCLCA2. This elevated expression persisted during the first
96 h of hormone withdrawal, a situation that mimicks
involution (Figure 1).
Given the striking upregulation of mCLCA2 and mCLCA5
upon differentiation of the KIM-2 cells and during the
involution-like process precipitated by hormone withdrawal,
we wished to investigate the impact of Stat3 signalling.
Undifferentiated KIM-2 mammary epithelial cells were stimu-
lated with either LIF or OSM to activate Stat3 by phosphoryla-
tion. Basal levels of expression of mCLCA2 and mCLCA5
were low/undetectable in undifferentiated KIM-2 cells
(Figures 1b, 2a and b), but a modest increase in expression
of mCLCA2 was seen upon stimulation with both LIF
(Figure 2a) and OSM (Figure 2b) mirroring the upregulation
in phosphorylated Stat3 (pStat3). Modulation of mCLCA5
expression was not observed. As anticipated, expression of
mCLCA2 was also enhanced by stimulation of differentiated
KIM-2 cells with OSM, but intriguingly this resulted in a modest
decrease in mCLCA5 expression (Figure 2c), possibly
reflecting differences in receptor downstream signalling path-
ways in differentiated cells. This was also reflected in the
response of differentiated KIM-2 cells to LIF where upregula-
tion of pStat3 was not observed (Supplementary Figure 1),
despite continued expression of the LIF receptor at the
RNA level (data not shown).
These findings suggest that two of the key upstream
regulators of Stat3 during involution, namely LIF and OSM,
regulate CLCA expression in murine mammary epithelium,
possibly in a reciprocal manner, with mCLCA2 being induced,
while mCLCA5 is suppressed. This result prompted us to
investigate CLCA expression in vivo.
mCLCA1 and mCLCA2 are upregulated, and mCLCA5 is
downregulated, during involution in a Stat3-dependent
manner. Affymetrix (High Wycombe, UK) microarray data
that have been previously published,29 indicated that
mCLCA3 is expressed at very low levels (data not shown),
whereas expression of mCLCA1 is markedly upregulated
between 12 and 48 h of involution (first phase), and
subsequently maintained from 48 h onwards (conventionally
considered the onset of the murine irreversible second
phase; Figure 3a).
To further interrogate a possible relationship between Stat3
activity and CLCA protein expression, we utilized mice with a
mammary epithelial cell-specific conditional deletion of Stat3
(Stat3fl/fl; BLG-Cre; hereafter referred to as Stat3 KO) and
compared these with age-matched controls lacking Cre
expression (control). Using qRT-PCR, we compared expres-
sion of mCLCA1, mCLCA2 and mCLCA5 during lactation and
involution, utilizing samples collected at 42 h involution, close
to the onset of the irreversible phase (unpublished data).
mCLCA1, mCLCA2 and mCLCA5 are all significantly
upregulated during involution, particularly, at the onset of the
second phase. Strikingly, expression of mCLCA1 and
mCLCA2 is almost entirely abrogated in the absence of
epithelial Stat3 (Figures 3b and c). Conversely, mCLCA5
expression exhibits a different pattern of expression reaching
maximal levels at the 42 h of involution ‘switch point’ to
irreversibility, and thereafter declining. Interestingly, expres-
sion is not abrogated by deletion of Stat3, and is instead
significantly upregulated in the Stat3 KO mice at 24, 72 and
Figure 2 Undifferentiated mammary epithelial KIM-2 cells exhibit low levels of
expression of mCLCA2 and mCLCA5, and expression of mCLCA2 may be
upregulated upon stimulation with LIF or OSM. Differentiated KIM-2 cells upregulate
expression of mCLCA2 upon stimulation with OSM and downregulate expression of
mCLCA5. (a) RT-PCR analysis for mCLCA2, mCLCA5 and cyclophilin A (house-
keeping gene), and western blot analysis of phosphorylated Stat3 (pStat3) and
tubulin expression in undifferentiated KIM-2 cells stimulated with either vehicle or 10
or 20 ng/ml LIF. Two biological repeats are shown. (b) RT-PCR analysis for mCLCA2,
mCLCA5 and cyclophilin A, and western blot analysis of pStat3 and tubulin
expression in undifferentiated KIM-2 cells stimulated with either vehicle or 25 ng/ml
OSM. Two (vehicle) or three (OSM stimulated) biological repeats are shown. (c) RT-
PCR analysis for mCLCA2, mCLCA5 and cyclophilin A, and western blot analysis of
pStat3 and tubulin expression in differentiated KIM-2 cells stimulated with either
vehicle or 25 ng/ml OSM. Three biological repeats are shown. NTC, no template
control
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96 h of involution (Figure 3d). This correlates with the
observation that mCLCA5 is downregulated upon stimulation
of Stat3 activity in OSM-stimulated differentiated KIM-2 cells
(Figure 2c).
At 96 h of involution, modest expression of mCLCA5 is
detectable in mammary epithelial cells in both control and
Stat3 KO mice (Figure 4a and Supplementary Figure 2A). In
control animals, expression of mCLCA5 is multifocally variable
in its intensity, which may reflect differing levels of mammary
alveolar regression within the gland at this time (Figure 4b).
Correlating with the qRT-PCR data (Figure 3d), there is
apparent increased expression of mCLCA5 in the absence of
epithelial Stat3 signalling (Figure 4b and Supplementary
Figure 2B). Intriguingly, mCLCA5 is present in some intralum-
inal shed (dying) epithelial cells, although this is not a uniform
finding.
mCLCA5 and Stat3 may be reciprocally expressed during
tumourigenesis. We considered our observations in the
Stat3 KO mice to be highly relevant, given that constitutively
active Stat3 signalling is observed in approximately half of
primary breast cancers30 and that mCLCA5 is the murine
orthologue of the human putative tumour suppressor
hCLCA2, as previously discussed.20 It therefore appeared
logical that Stat3 signalling in tumours may have an inhibitory
effect upon expression of mCLCA5 and thus we explored this
hypothesis in the 4T1 murine syngeneic tumour model, which
has previously been reported to exhibit minimal expression of
mCLCA5.22
Implantation of 4T1 cells into the mammary fat pad of
syngeneic mice resulted in the development of fast growing
tumours comprising pleomorphic cells with a high mitotic
rate as previously described31,32 (Figures 5a–c). pStat3 was
upregulated in tumours derived from implantation of 4T1 cells,
compared with 4T1 cells maintained in vitro, in which pStat3
levels are low. Unexpectedly, we discovered that a higher level
of pStat3 accompanied a higher level of mCLCA5 expression
(Figure 5d). Interestingly, the majority of nuclear pStat3
expression was seen at the invasive edge of the tumour,
where cells with morphology consistent with tumour cells,
fibroblasts and immune cells, all exhibited nuclear pStat3
localization (Figure 6a).33 The subgross pattern of localization
of mCLCA5 was strikingly similar: punctate cytoplasmic
mCLCA5 expression was present predominantly at the edge
of the mass (Figure 6b). Granular or punctate cytoplasmic
staining could be consistent with the expression of a protein
within intracellular organelles – potentially a secretory
product.15
The tumours resulting from implantation of the 4T1 cells
were morphologically heterogeneous, with abundant expres-
sion of vimentin (Supplementary Figure 3). Cells expressing
E-cadherin and vimentin were admixed at the invasive front,
with multifocal apparent co-expression (Figure 7a and
Supplementary Figure 4A). This observation underlines the
Figure 3 mCLCA1 and mCLCA2 are profoundly upregulated during involution in a Stat3-dependent manner. By contrast, mCLCA5 is upregulated in the absence of epithelial
Stat3 signalling. (a) Microarray expression profile for mCLCA1 derived from 12 different time points in the developmental cycle of the mouse mammary gland. Expression of
mCLCA1 (b), mCLCA2 (c) and mCLCA5 (d) in control and Stat3 KO mice measured by qRT-PCR relative to expression of cyclophilin A (housekeeping gene). Values are
mean± S.D. from at least three biological repeats; *Po0.05, **Po0.01 as determined by Student’s t-test. d G, days gestation; dL, days lactation; d Lac, days lactation; hI, hours
involution; h Inv, hours involution; V, virgin
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potential importance of localization of mCLCA5 to the invasive
front, where cells may be assuming more mesenchymal
characteristics. As 4T1 cells have been previously demon-
strated to express modest amounts of vimentin and robust
levels of E-cadherin in vitro,34 expression of both proteins in vivo
was perhaps unsurprising, given the aggressive phenotype of
the tumours. Although the cellular heterogeneity and apparent
co-expression of vimentin and E-cadherin by the 4T1 cells
precluded definitive identification, by co-staining, of the
mCLCA5 expressing cells as 4T1 cells, we identified E-cad-
herin and mCLCA5 dual-positive cells that we considered likely
to be 4T1 cells (Figure 7b and Supplementary Figure 4B).
Using immunofluorescence to further characterize the
cellular populations expressing mCLCA5 and nuclear Stat3
(as a surrogate read-out of Stat3 activity), we identified at least
two different cell populations at the edge of the tumour
Figure 4 mCLCA5 protein is expressed during mammary gland involution and is subjectively more abundant in the absence of epithelial Stat3 signalling.
Immunofluorescence staining for mCLCA5 (red) and E-cadherin (green), and DNA (Hoechst; blue) on control and Stat3 KO tissue at 96 h of involution. Scale bar= 50 μm (a) and
10 μm (b). Staining of residual milk (*) was considered non-specific. Some, but not all shed cells exhibited positive staining for mCLCA5 (arrowhead). Representative images are
displayed. Sections from five mice were examined (control n= 2; Stat3 KO n= 3)
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(Figure 7c and Supplementary Figure 4C). Strikingly, the
majority of cells either exhibited intense nuclear staining for
Stat3 or strong punctate cytoplasmic staining for mCLCA5, but
very few cells were identified that co-expressed mCLCA5 in
the presence of nuclear Stat3. Although some of the cells
expressing Stat3 exhibited morphology consistent with stro-
mal cells or tumour-associated immune cells, others were
consistent with neoplastic cells (Figure 7c).
We therefore suggest that in individual neoplastic cells, the
negative regulation of mCLCA5 by pStat3 remains functional.
Although both mCLCA5 and pStat3 are expressed predomi-
nantly at the invasive edge of the tumour, minimal co-
localization of nuclear Stat3 and cytoplasmic mCLCA5 is
observed. It seems likely that mCLCA5 expression may be
predominantly in the tumour cells, whereas pStat3 nuclear
localization is seen in both the tumour cells and immune and
stromal compartments at the invasive front. Thus, activity of
pStat3, a known breast cancer oncogene,30,35 is likely to be
critical to the invasive nature of the neoplastic cells at the
tumour margin.
Other investigators have suggested that CLCA proteinsmay
act as extracellular signalling molecules17,36 and it is tempting
to speculatively attribute such as role to mCLCA5 in this
context at the invasive edge of the tumour (Figure 7).
Discussion
We have demonstrated that mCLCA1 and mCLCA2 are
profoundly downregulated in the absence of mammary
epithelial Stat3 signalling during post-lactational regression,
suggesting a close direct or indirect relationship between
Stat3 activity and expression of mCLCA1 and mCLCA2. This
exciting finding warrants further investigation in the context of
the function of these proteins within the mammary gland.
Furthermore, our data suggest that during mammary gland
regression, mCLCA5 expression is partially suppressed by
epithelial Stat3 activity. Given the pro-tumourigenic nature of
the involution mammary microenvironment, this is an impor-
tant finding. However, data from orthotopic tumours derived
from implantation of 4T1 cells into mice suggest that the
relationship between mCLCA5 and Stat3 activity may be
complex, with separate populations of cells expressing high
levels of mCLCA5 or transcriptionally active (nuclear) Stat3.
This suggests that Stat3 retains a suppressive effect on
Figure 5 mCLCA5 is expressed in tumours resulting from implantation of 4T1 cells. (a and b) Representative photomicrographs demonstrating that orthotopic tumours
derived from 4T1 cells are densely cellular, with minimal stroma and a moderately to markedly pleomorphic phenotype with numerous mitoses. Haematoxylin and eosin stain.
Scale bar= 300 μm (a) and 30 μm (b). Arrowhead indicates a mitotic figure. Several mitoses are present in this field. (c) Average tumour size in mm3 for tumours derived from
injection of 1 × 105 4T1 cells in the mammary fat pad. Values are mean±S.D. from four biological repeats. (d) RT-PCR analysis for mCLCA5 and cyclophilin A, and western blot
analysis of phosphorylated Stat3 (pStat3), total Stat3 and tubulin expression in 4T1 cells maintained in culture (4T1 in vitro) and in tumours resulting from implantation of 4T1 cells
into the mammary fat pad of syngeneic mice (4T1 in vivo). Three independent biological repeats are shown for 4T1 in vitro; for 4T1 implanted in mice, four tumours from separate
individuals are represented. NTC, no template control
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mCLCA5 expression in 4T1 tumour cells. It is in accordance
with the findings of others, and therefore tempting to
speculate, that downregulation of mCLCA5 in the presence
of cells expressing Stat3 activity reflects an invasive pheno-
type in these cells and potential epithelial–mesenchymal
transition.16,22,24
However, our data also raise the question of the role of the
observed mCLCA5 expression at the invasive front. One
interpretation is that mCLCA5 expression at the invasive edge
may be beneficial to tumour growth with mCLCA5 acting in a
non-cell autonomous manner to augment tumour cell
proliferation.37 However, in this context it is important to note
the compelling data demonstrating that re-expression of
mCLCA5 in 4T1 cells inhibits proliferation22 and that loss of
hCLCA2 expression in human MCF10A cells augments
proliferation of the cells,24 whereas re-expression elicits a
reduction in tumour cell growth.19 In the in vivo 4T1 murine
model described in our study, cellular behaviour may be
influenced by the presence of subpopulations of neoplastic
cells in which either Stat3 activity suppresses mCLCA5
expression, or mCLCA5 is expressed in the absence of Stat3
activity. The influence of the immune cell compartment also
needs to be considered particularly given that the 4T1 model
involves introduction of syngeneic tumour cells into immune-
competent mice. It is possible that mCLCA5 secretion is
stimulated in host cells, such as stromal components or
immune cells, in an attempt to negatively regulate tumour
growth. Currently, the role of mCLCA5 at the invasive front of
the tumour is unclear. Future work will require development of
inducible models of mCLCA5 expression and/or Stat3 activity
in vivo in different cell types to understand the relationship
between the key oncogene Stat3 and the intriguing factor
mCLCA5.
Although in normal mammary gland, Stat3 regulates cell
death, breast cancer cells frequently become addicted to Stat3
and require Stat3 activity for survival. Our data demonstrate
that Stat3 is a negative regulator of mCLCA5 duringmammary
gland involution, and that in tumourigenesis in an immune-
competent murine model, mCLCA5 expression is suppressed
in cells with high levels of nuclear Stat3. Stat3 appears to be a
cell autonomous negative regulator of this protein.
Materials and Methods
Cell culture. Maintenance and differentiation of KIM-2 cells and instigation of
hormone withdrawal, were as previously described.28 Human LIF (a generous gift
from Dr Jennifer Nichols) or recombinant mouse OSM (495-MO, R&D Systems,
Abingdon, UK) were used at a final concentration of 10 or 20 ng/ml (LIF), or 25 ng/
ml (OSM). For imaging, KIM-2 cells were differentiated in 35 mm diameter glass
bottom dishes (81158, ibidi, Planegg, Martinsried, Germany). Murine 4T1 cells were
purchased from ATCC (Teddington, Middlesex, UK) and were maintained according
to ATCC protocols.
RT-PCR and qRT-PCR. Standard protocols were followed.38 The primer
sequences utilized are detailed in Supplementary Table 1.
Immunoblotting. Standard protocols were followed.38 Antibodies employed
were: anti-phospho-Stat3 (1:1000; Tyr705: #9131), anti-Stat3 (1:1000; #12640), anti-
GAPDH (1:5000; #5174) (all Cell Signaling Technology, Danvers, MA, USA), and
anti-alpha-tubulin (1:5000; AB6160, Abcam, Cambridge, UK).
Animal husbandry. Stat3fl/fl; BLG-Cre mice39,40 were utilized and involution
induced as previously described.9 All animals were treated according to the local
ethical committee and the UK Home Office guidelines.
4T1 tumour model. A final volume of 16 μl containing 1 × 105 4T1 cells with
matrigel (basement membrane matrix growth factor reduced; BD 354230; BD
Biosciences, Erembodegem, Belgium) was injected into the right- or left-fourth
mammary gland fat pad of ~ 12-week-old virgin Balb/c mice under anaesthesia and
analgesia.41 Tumour development was monitored, mice were killed and tumours
were harvested at day 25 post injection. Tumour tissue (lacking normal tissue
margins) was collected for RNA and protein extraction. Tissue for histological
Figure 6 Distinct cell populations express mCLCA5 and nuclear Stat3 at the
invasive edge of tumours resulting from implantation of 4T1 cells. (a and b)
Immunohistochemical staining for pStat3 (a) and mCLCA5 (b) on adjacent sections of
orthotopic tumours derived from implantation of 4T1 cells. Haematoxylin counterstain.
Scale bar= 500 μm. The micrographs at higher magnification show representative
staining from the edge and centre of the mass as indicated. Scale bar= 30 μm
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sectioning was dissected. Formalin fixation, histological sectioning and staining
followed routine protocols.
Immunostaining. KIM-2 cells in glass bottom dishes were fixed for 10 min in
ice cold methanol and immunofluorescence staining for E-cadherin (1:400; #3195;
Cell Signaling Technology) was carried out following a standard protocol.
Paraffin embedded tumour specimens were prepared as three micron sections on
positively charged slides (Snowcoat; Surgipath Europe Ltd, Peterborough, UK).
Immunohistochemical staining for mCLCA5 (1:500; sc99224; Santa Cruz
Biotechnology, Dallas, TX, USA), vimentin (1:500; #5741) and murine pStat3
(1:100; Tyr705: #9145) (both Cell Signaling Technology) was carried out using a
routine protocol employing an automated immunohistochemistry system (Dako
Autostainer; Dako, Ely, UK).
Immunofluoresence staining for E-cadherin (1:500; 610182, BD Biosciences,
Oxford Science Park, Oxford, UK), mCLCA5 (1:100; sc99224; Santa Cruz
Biotechnology), vimentin (1:200; #5741) and murine total Stat3 (1:100; #9139) (both
Cell Signaling Technology, Danvers, MA, USA) was carried out following
de-paraffinization and antigen retrieval for 20 min at 90 °C using Dako Envision
Flex Target Antigen Retrieval Solution High pH in a PT Link and Pre-Treatment
Module for Tissue Specimens (both Dako). For Fc receptor blocking prior to staining
for murine total Stat3 (murine monoclonal antibody), anti-mouse CD16/CD32 clone
93 was utilized (1:500; 14-0161-85, eBioscience Ltd, Cheshire, UK). Isotype- and
species-matched immunoglobulins were used as a negative control.
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